About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
Patiromer
- Company
- Vifor Pharma, Inc.
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- 4 recruiting
Efficacy results: Not yet reported
4 recruiting studies currently listed on ClinicalTrials.gov.
Data source: ClinicalTrials.gov · trial data as of Sep 22, 2026
Find a Clinical Trial Near Me
See recruiting studies for Patiromer and check eligibility with the study team.
Trial details
-
Recruiting NCT NCT05766839
Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels
Not yet reported Vifor Pharma, Inc. 36 participants Est. completion 2030-12-01 37 sites Stand-aloneOther conditions: HyperkalemiaView official trial listing → -
Recruiting NCT NCT05828823
Incremental Hemodialysis: The TwoPlus Trial
Not yet reported Wake Forest University Health Sciences 350 participants Est. completion 2031-01 10 sites Stand-aloneOther conditions: End-Stage Kidney DiseaseView official trial listing → -
Recruiting NCT NCT06256991
Potassium Correction for RAAS Optimization in Chronic Kidney Disease
Not yet reported University Medical Center Groningen 44 participants Est. completion 2027-12 1 site Stand-aloneChronic kidney disease Other conditions: Hyperkalemia, HypertensionView official trial listing → -
Recruiting NCT NCT06858280
Patiromer and Diet/hrQoL in Chronic Dialysis
Not yet reported Mario Negri Institute for Pharmacological Research 40 participants Est. completion 2026-07 1 site Stand-aloneChronic kidney disease Other conditions: Hyperkalaemia, Dietary InterventionView official trial listing → -
Completed NCT NCT00868439
Evaluation of Patiromer in Heart Failure Patients
Not yet reported Relypsa, Inc. 120 participants Est. completion 2009-12 33 sitesHeart failure Other conditions: HyperkalemiaView official trial listing → -
Completed NCT NCT01130597
Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease
Not yet reported Relypsa, Inc. 63 participants Est. completion 2010-09 13 sites Stand-aloneHeart failureView official trial listing → -
Completed NCT NCT01371747
Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)
Not yet reported Relypsa, Inc. 324 participants Est. completion 2013-06 43 sites Stand-aloneChronic kidney disease Other conditions: Hypertension, HyperkalemiaView official trial listing → -
Completed NCT NCT01810939
A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
Not yet reported Relypsa, Inc. 243 participants Est. completion 2013-08 58 sitesChronic kidney disease Other conditions: Hyperkalemia (HK)View official trial listing → -
Terminated NCT NCT02033317
An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis
Not yet reported Relypsa, Inc. 6 participants Est. completion 2008-12 2 sites Stand-aloneOther conditions: HyperkalemiaView official trial listing → -
Completed NCT NCT02694744
Patiromer With or Without Food for the Treatment of Hyperkalemia
Not yet reported Relypsa, Inc. 114 participants Est. completion 2016-08 29 sites Stand-aloneOther conditions: HyperkalemiaView official trial listing → -
Completed NCT NCT02823626
High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure
The University of Texas Health Science Center at San Antonio 48 participants Est. completion 2018-04 1 siteHeart failureView official trial listing → -
Completed NCT NCT02933450
Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)
Not yet reported Baylor College of Medicine 43 participants Est. completion 2017-08 1 siteOther conditions: Kidney Failure, ChronicView official trial listing → -
Completed NCT NCT03071263
Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
Not yet reported Relypsa, Inc. 295 participants Est. completion 2018-11-27 40 sites Stand-aloneOther conditions: Hyperkalemia, Resistant HypertensionView official trial listing → -
Terminated NCT NCT03087058
Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia
Not yet reported Vifor Pharma, Inc. 23 participants Est. completion 2021-04-30 30 sites Stand-aloneOther conditions: HyperkalemiaView official trial listing → -
Completed NCT NCT03183778
Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.
Not yet reported NYU Langone Health 3 participants Est. completion 2019-08-01 1 site Stand-aloneChronic kidney disease Other conditions: HyperkalemiaView official trial listing → -
Completed NCT NCT03229265
Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer
Not yet reported The Rogosin Institute 8 participants Est. completion 2019-08-07 1 site Stand-aloneOther conditions: Hyperkalemia, Kidney TransplantView official trial listing → -
Completed NCT NCT03326583
The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia
Not yet reported Dominic Raj 27 participants Est. completion 2020-12-31 1 site Stand-aloneOther conditions: ESRD, Hyperkalemia, End Stage Renal DiseaseView official trial listing → -
Terminated NCT NCT03597035
Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On
Not yet reported University Hospitals Cleveland Medical Center 8 participants Est. completion 2020-07-31 1 site Stand-aloneType 2 diabetes Other conditions: HyperkalemiaView official trial listing → -
Completed NCT NCT03740048
A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease
Not yet reported Wake Forest University Health Sciences 51 participants Est. completion 2021-11-04 1 site Stand-aloneOther conditions: End Stage Renal Failure on DialysisView official trial listing → -
Completed NCT NCT03781089
Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients
Not yet reported Duke University 36 participants Est. completion 2023-03-15 1 site Stand-aloneOther conditions: Hyperkalemia, End Stage Renal DiseaseView official trial listing → -
Completed NCT NCT03799926
Exploratory Study of ZG-801 for the Treatment of Hyperkalemia
Not yet reported Zeria Pharmaceutical 184 participants Est. completion 2021-02-02 1 site Stand-aloneOther conditions: HyperkalemiaView official trial listing → -
Completed NCT NCT03888066
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
Not yet reported Vifor Pharma, Inc. 1195 participants Est. completion 2021-09-02 415 sites Stand-aloneOther conditions: HyperkalemiaView official trial listing → -
Terminated NCT NCT04142788
RELieving Increasing oEdema Due to Heart Failure
Not yet reported NHS Greater Glasgow and Clyde 19 participants Est. completion 2022-12-20 11 sites Stand-aloneHeart failureView official trial listing → -
Terminated NCT NCT04443608
Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management
Not yet reported Comprehensive Research Associates 115 participants Est. completion 2023-06-03 19 sitesOther conditions: HyperkalemiaView official trial listing → -
Completed NCT NCT04566653
Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia
AstraZeneca 147 participants Est. completion 2022-01-12 18 sitesHeart failureChronic kidney diseaseView official trial listing → -
Terminated NCT NCT04585542
Comparison of Potassium Binders in the ER
Not yet reported University of California, Irvine 37 participants Est. completion 2025-01-31 1 site Stand-aloneOther conditions: Acute Hyperkalemia, Oral Potassium BindersView official trial listing → -
Completed NCT NCT05029310
Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients
Not yet reported Oslo University Hospital 13 participants Est. completion 2023-02-01 1 site Stand-aloneOther conditions: Hyperkalemia, Kidney TransplantView official trial listing → -
Active, not recruiting NCT NCT05050110
Evaluation of Increased Fruits and Vegetables Consumption in Chronic Kidney Disease
Not yet reported Nand Wadhwa 13 participants Est. completion 2026-12 1 siteChronic kidney diseaseView official trial listing → -
Completed NCT NCT05136664
Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects
Not yet reported Vifor Fresenius Medical Care Renal Pharma 262 participants Est. completion 2025-11-18 28 sites Stand-aloneOther conditions: Hyperkalemia, Renal Insufficiency, ChronicView official trial listing → -
Terminated NCT NCT05786469
Patiromer Trial in CKD Stage IIIB to V
Not yet reported Mario Negri Institute for Pharmacological Research 2 participants Est. completion 2024-11-07 1 site Stand-aloneOther conditions: HyperkalemiaView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Also known as: Patiromer, VELTASSA
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.